Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 5/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | UBE2M | P61081 | 1/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4786817 | 0.83 | FADS1 (0.59) | FADS1ACHEBACE1HTR7KDM1A | |
| SCHEMBL4787090 | 0.81 | FADS1 (0.50) | FADS1ACHE | |
| SCHEMBL4787131 | 0.79 | FADS1 (0.51) | FADS1ACHEKDM1AMAOAMAOB | |
| SCHEMBL4805296 | 0.78 | FADS1 (0.78) | FADS1BACE1KDM1AMAOAMAOB | |
| SCHEMBL4785224 | 0.78 | FADS1 (0.78) | FADS1BACE1KDM1AMAOAMAOB | |
| SCHEMBL4785195 | 0.78 | FADS1 (0.57) | FADS1ACHEBACE1KDM1AMAOA | |
| SCHEMBL4785262 | 0.76 | FADS1 (0.71) | FADS1BACE1KDM1AMAOAMAOB | |
| SCHEMBL4740962 | 0.74 | FADS1 (0.71) | FADS1BACE1KDM1AMAOAMAOB | |
| SCHEMBL4740963 | 0.74 | FADS1 (0.71) | FADS1BACE1KDM1AMAOAMAOB | |
| SCHEMBL4797343 | 0.73 | FADS1 (0.66) | FADS1KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | LEXICON PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | LEXICON PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | TNF, IL6, CXCL8 | FADS1 1059/4885ACHE 13/4885BACE1 2861/4885 |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | CPT1B, CPT1A, SHBG | FADS1 270/4885ACHE 449/4885BACE1 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.